Finkarma

Follow FINKARMA NEWS UPDATES channel on Telegram for the latest news. t.me/FINKARMA_News_…

📊 1. Impressive Q3 FY25 Performance: -Revenue: ₹1,265 Cr (+24% YoY) 📈 -EBITDA: ₹670 Cr (+20% YoY), Margin: 52.9% 🚀 -Net Profit: ₹336 Cr (+32% YoY) 💰 -Cargo Volumes: 29.4 MT (+5% YoY); 3rd-party Cargo: 49% (Up from 39%) ✅ 📅 2. Robust 9M FY25 Results: -Revenue: ₹3,457 Cr (+22% YoY) 💹 -EBITDA: ₹1,885 Cr (+22% YoY) 📈 -Net Profit: ₹1,006 Cr (+21% YoY) 🔥 -Cargo Volumes: 85.7 MT (+11% YoY); 3rd-party Cargo soared 45% YoY 🚛 🎯 3. Clear Strategic Priorities: ✅ Expand port capacity from 174 mtpa to 400 mtpa by FY30 ✅ Grow logistics segment to ₹8,000 Cr revenue with 25% EBITDA margin by FY30 ✅ Actively seek strategic & value-accretive acquisitions 💼 🚧 4. Exciting Expansion Projects Underway: Brownfield: -Jaigarh & Dharamtar (+36 mtpa by FY27) -Goa Port (+6.5 mtpa by FY25) Greenfield: -Keni Port (Karnataka, 30 mtpa by FY29) -Jatadhar Port (Odisha, 30 mtpa by FY28) Terminals: -JNPA Liquid (4.5 mtpa by FY26) -Tuticorin Bulk (7 mtpa by FY26) 🚛 5. Logistics Expansion - A Strategic Leap: -Investing ₹9,000 Cr by FY30 -Acquired 70.37% in Navkar Corp for pan-India logistics -Developing 15-20 terminals nationally -Asset-light via Gati Shakti terminals for cost efficiency ⚡️ ⚙️ 6. Specialized Infrastructure - Pipeline Project: -302 km Slurry Pipeline (Odisha), 30 mtpa capacity ✅ -Operational by April 2027 supporting JSW Utkal Steel 🏭 💪 7. Solid Financial Health: -Low net debt: ₹827 Cr -Net debt-to-EBITDA at just 0.4x -Strong cash reserves: ₹4,845 Cr, ensuring ample growth funding 💰 🌱 8. Sustainability Leadership (ESG): -Rated "Low Risk" by Sustainalytics ✅ -Increasing renewable energy usage ♻️ -Commitment to reduce emissions & environmental footprint 🌍 🚀 9. Competitive Advantages: -Rising 3rd-party cargo (now 49%) enhancing stability & profitability 📦 -Strategically located ports enabling seamless logistics & cost optimization 🌐 🗣️ 10. Management Optimism & Guidance: -Confident on sustaining 10%+ annual cargo growth beyond FY25 📈 -Targeting higher EBITDA margins (58% ports, 25% logistics by FY30) 📊 🔮 📌 Bottom Line: ✅ Clear & aggressive expansion strategy ✅ Healthy financials & balance sheet ✅ Expanding high-margin third-party logistics ✅ Robust sector tailwinds from Govt. initiatives (Sagarmala, NIP) ✅ Solid execution track record & visionary leadership JSW Infrastructure is exceptionally positioned for sustainable growth.Definitely a stock to watch! 🚢📈 📲 #JSWInfra #Ports #Logistics #Q3Results #InfraGrowth #StockMarket #StocksToWatch #IndiaGrowth

🚢 Detailed Analysis on JSW Infrastructure 🧵👇 by @FUNDAFORSTOCKS

🚀 Mega Thread: Indian CRDMOs – The Next Pharma Frontier 🇮🇳💊 By @FUNDAFORSTOCKS 🧵 1⃣ What are CRDMOs? 🔬 Contract Research, Development & Manufacturing Organizations 📌 Offer Pharma end-to-end services: Discovery→Development→Manufacturing 🚀 Help Pharma reduce costs, speed up timelines, manage risks, and deliver complex molecules 🌎 2⃣ Global CRDMO Market Snapshot 📊 Current Market: ~US$197 bn (2023) 🚀 Projected Growth: ~9% CAGR, reaching ~US$300 bn by 2028 🔥 Innovator-focused CRDMO (~US$140 bn) growing even faster 🎯 Outsourcing from Pharma jumped from <20% (2000s) to 42% today, heading towards ~47% by 2028 🔥 3⃣ Why CRDMOs Are Booming Globally 💰 Drug development costs skyrocketing (>US$1 bn per drug, up 10x since the 1970s) ⚠️ Declining R&D success rates (~11% today from ~25% earlier) 🚧 Rising complexity in drug discovery (Biologics, ADCs, Peptides) 🌐 Small & mid-sized Pharma increasingly dependent on specialized outsourcing 🇮🇳 4⃣ India's CRDMO Boom: Huge Opportunity 📌 Current Market Size: ~US$3 bn (2024) 🚀 Projected Size: ~US$12 bn by 2034 (14% CAGR) 🌏 Capturing ~30% incremental demand from global innovators shifting away from China (China+1) ✨ 5⃣ India's Key Competitive Advantages 💡 Cost-effective R&D (~60% cheaper) & Manufacturing (~75% cheaper) vs. US/EU 🎖️ Largest number of US FDA-approved Pharma plants after the US 🎓 Massive talent pool (~24k STEM PhDs annually) 🛡️ Strengthening IP regime and supportive Govt. policies (PLI schemes, Biotech clusters) 📌 6⃣ Major Growth Drivers in India 🌐 Global Pharma reducing dependency on China (current China market: ~US$28 bn) 🧬 Increased demand for specialized therapies (ADCs, HPAPIs, Peptides, Oligonucleotides) 🤝 Growing preference for integrated services (discovery through commercialization) 💉 Higher regulatory scrutiny pushing innovators to India (reliable quality standards) 🏅 7⃣ Top Indian CRDMOs ✅ Piramal Pharma ✅ Syngene International ✅ Sai Life Sciences 💠 8⃣ Piramal Pharma 🔹 Robust diversified capabilities: ADCs, HPAPIs, sterile injectables 🔹 Strong molecule pipeline: 150+ molecules, 14-15 launches expected by FY28 🔹 EBITDA margin expansion (~630 bps FY24–28E) 🔹 Significant Free Cash Flow generation (~₹17 bn FY25–28E), improved balance sheet 💎 9⃣ Syngene International 🔸 India's leading integrated CRDMO player (Discovery to Commercialization) 🔸 Strong Biologics and small molecule expertise, reliable regulatory compliance 🔸 Robust client base (400+ global innovators) 🔸 Integrated platform "SynVent" (~18-20 active projects) driving growth 🔸 Strong financial trajectory (14-19% CAGR: Sales, EBITDA, EPS FY24–28E) ♾ 🔟 Sai Life Sciences ▫️ Integrated discovery-to-manufacturing capabilities, strong molecule pipeline (170+) ▫️ Healthy growth (EBITDA ~29% CAGR FY24–28E) 🧬 1⃣1⃣ India's Advanced CRDMO Technological Capabilities 🌱 Flow Chemistry, Continuous Manufacturing, Recombinant DNA, Electrochemistry, Fermentation ⚗️ Complex therapeutics: Antibody-Drug Conjugates (ADCs), Peptides, Highly Potent APIs (HPAPIs), Biologics, Cell & Gene therapies 💡 Continuous investments strengthening global competitive positioning 🤖 1⃣2⃣ AI & Digitalization Transforming CRDMOs 🚀 AI & ML enabling faster molecule screening, precision targeting, quicker clinical trials 🧬 Complexity shifting towards biology/DMPK studies, away from traditional computational chemistry ⏳ Accelerating discovery timelines, improving overall efficiency, and driving down costs 🤝 1⃣3⃣ Evolution of Pharma-CRDMO Partnerships 🔄 Moving from simple vendor-client to strategic risk-sharing partnerships 🏦 Increased joint ventures, co-investments, and shared R&D responsibilities 📈 Growing demand for integrated end-to-end services reducing complexities, improving timelines & quality ⚡ 1⃣4⃣ Potential Risks & Challenges 🐢 Sluggish biotech funding recovery impacting small innovators 🗳️ Uncertainty regarding US Biosecure Act potentially slowing China+1 diversification 🏢 Rising competition from Pharma’s in-house Global Capability Centers (GCCs) 📌 Tariff-related risks indirectly affecting Indian competitiveness 🌟 1⃣5⃣ Competitive Benchmarking: India vs Global 🌐 Strong global competitiveness in small molecules & regulatory compliance 🔍 Gaps in biologics and presence in global innovation hubs (US/UK), ongoing efforts to bridge through talent acquisition & strategic partnerships 💡 Active capacity expansions and capability upgrades across Indian players 📈 1⃣6⃣ Long-Term CRDMO Outlook 🎯 Indian CRDMO market forecasted at US$12 bn by 2034 (~14% CAGR) 🌏 Multiple structural tailwinds: global outsourcing, innovation demand, China+1 shift, and supportive policies 🚀 Strategic investments in advanced capabilities securing sustained long-term growth 🎖️ 📌 Final Takeaways for Investors 🔑 Prioritize integrated CRDMOs with robust tech capabilities & solid pipeline 💡 Favor disciplined valuations, global client networks, and strong R&D capabilities ✅ CONCLUSION: Indian CRDMOs stand at the cusp of multi-year explosive growth. Investors should strategically position themselves in companies with integrated service offerings, advanced technological capabilities, robust pipelines, and attractive valuations. ⚠️Not a BUY/SELL advice⚠️ Like 👍 & Repost 🔄 if you found this insightful! 📌 Follow @FUNDAFORSTOCKS , @finkarmaIN for more industry deep dives & actionable market insights! #CRDMO #Pharma #India #Biotech #Investing #Stocks #MarketInsights

1️⃣ India’s Largest Airline – Overview -Fleet size: 437 aircraft; plans for 600+ aircraft by FY2030. -Passenger volume: Welcomed 113 million passengers in FY25. -Daily flights: Operating over 2,200 flights/day, connecting 131 destinations (91 domestic, 40 international). 2️⃣ Strong Macro Tailwinds -India set to become 5th largest economy globally. -Domestic aviation passengers expected to double (510M by FY2030). -High growth driven by rising incomes, Gen-Z travelers, and infrastructure expansion. 3️⃣ Untapped International Opportunity -India’s international seats per capita remain low (0.06), huge room for growth. -Expanding international seat share from ~28% in FY25 to ~40% by FY30. -Adding wide-body aircraft (Airbus A350s & damp-leased Boeing 787s) and new Airbus A321 XLRs from FY26 for long-haul connectivity. 4️⃣ Cost Leadership and Efficiency -One of the lowest operational costs globally among LCCs. -Strong operational metrics: On-Time Performance (84.4%), Flight completion rate (99.5%), High aircraft utilization rates. -Extensive in-house maintenance & engineering capabilities to minimize downtime. 5️⃣ Robust Aircraft Order Book -Secured deliveries of 925 aircraft until 2035. -Recent landmark 500 aircraft Airbus order (largest ever single-airline order with Airbus). -Diverse fleet: A320neo, A321neo, ATR turboprops, A350 widebodies, and damp-leased Boeing 787s. 6️⃣ Premium Offerings & Ancillary Revenue Growth -Introduced "IndiGo Stretch" (Business Class) on selected routes, enhancing yields. -Strong ancillary revenue growth projected: targeting a 30% increase per passenger from FY24-FY26. -Successful loyalty program launch (BluChip): Over 2 million members enrolled in 5 months. 7️⃣ Digital Transformation & Customer Experience -Redesigned website & mobile app: 82% YoY growth in website traffic, 33% increase in mobile adoption. -Advanced tech initiatives: AI-enabled chatbot (6ESkai), automated baggage weighing (BagWatch), mobile breathalyzers (6E Digi Breathalyzer). -Enhanced direct sales channels (up 55%), improving margins and customer engagement. 8️⃣ Expanding CarGo Operations -Leveraging extensive domestic & international network for cargo. -Cargo capacity enhancements via wide-body aircraft (10 tons per flight) & freighters (20+ tons). -Positioned well to capture growth in logistics, e-commerce, and Make-in-India manufacturing exports. 9️⃣ Financial Strength & Profitability -FY25 financial performance strong with total income reaching INR 795 billion (up 18% YoY). -EBITDAR margins (ex-forex) of ~27%, showcasing consistent profitability. -Net profit after tax: INR 61 billion for trailing 12 months (Dec’24). -Robust cash reserves (INR 289 billion) provide ample financial flexibility. 🔟 ESG Commitment & Global Leadership -Emissions: Targeting 23% reduction in GHG emissions by FY2030 vs. FY16 baseline. -Fleet composed primarily of new-generation, fuel-efficient aircraft, ensuring minimal environmental footprint. -Global leader in diversity: employing the highest number of female pilots worldwide. -Strong CSR initiatives: Skill development, women empowerment, ecological sustainability (177k saplings planted), heritage conservation. 1️⃣1️⃣ Strategic Risk Management -Effective mitigation strategies in place for fuel volatility, forex fluctuations, inflation, regulatory changes, and supply-chain disruptions. -Proactively managing aircraft-on-ground (AOG) situations through secondary leases and damp leases, maintaining operational continuity. 1️⃣2️⃣ Recognition & Industry Accolades -Awarded Airline of the Year 2024. -Recognized for the Youngest Aircraft Fleet globally (2025). -Achievements in cargo excellence, customer experience, diversity inclusion, and sustainability practices. 📈 Future Growth Outlook (FY2026+) -Committed to continued double-digit capacity and passenger growth. -Network expansion: Targeting 145+ destinations within the next year. -Sustained investment of INR 300 crores into aviation innovation and tech-driven ventures. 🌐 Conclusion IndiGo is strongly positioned for sustained market leadership, underpinned by strategic internationalization, disciplined financial management, and industry-leading ESG practices. #IndiGo #InvestorDay #IndianAviation #AviationNews #ESG #Sustainability #Growth #Stocks #India

🧵 A detailed breakdown of IndiGo’s ambitious growth roadmap, financial health, strategic plans from their latest investor presentation: By @FUNDAFORSTOCKS ✈️ IndiGo Investor Presentation Highlights (March 2025)

Follow @finkarmaIN Follow @FUNDAFORSTOCKS ✅Like ✅Follow ✅Repost

📢 Final Thoughts: The economy is at a tipping point. Tariffs, inflation, currency shifts, & trade wars could lead to major economic disruptions. Will policymakers act in time? Or are we heading toward a financial crisis? 🤔 What do YOU think? Drop your thoughts below! 👇💬 #Economy #TradeWars #Inflation

🧵 THREAD: Market FALL? Trump, Tariffs, Currency & CHINA – A Deep Economic Analysis 📉🌎 By @FUNDAFORSTOCKS 🚨 The global economy is shifting rapidly! This thread breaks down the key issues affecting markets today: ✅ Trump’s trade policies & tariffs ✅ Inflation & interest rates ✅ Financial markets vs. real economy ✅ Emerging market struggles ✅ China’s overproduction crisis A MUST-READ 🧵👇

Follow @FUNDAFORSTOCKS x.com/FUNDAFORSTOCKS

Follow @finkarmaIN x.com/finkarmaIN

Capex Plans: Big Investments Coming! 💰 💰 Total Investment: ₹9.5B (FY25-27) 🔹 New plants for MEHQ, Guaiacol, Anisole, Iso Amylene, 4-MAP 🔹 Major capacity expansion by Q4FY25